Difference between revisions of "Topotecan (Hycamtin)"
m |
|||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 22: | Line 15: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Irritant chemotherapy]] | ||
| + | [[Category:Topoisomerase inhibitors]] | ||
| + | |||
| + | [[Category:Aggressive Non-Hodgkin lymphoma medications]] | ||
| + | [[Category:Bone cancer medications]] | ||
| + | [[Category:Cervical cancer medications]] | ||
| + | [[Category:Ovarian cancer medications]] | ||
| + | [[Category:Small cell lung cancer medications]] | ||
| + | [[Category:Uterine cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 1996]] | ||
Revision as of 15:38, 15 July 2014
General information
Class/mechanism: Topoisomerase I inhibitor. Topotecan binds to the topoisomerase I-DNA complex and prevents the religation of single strand breaks that were originally created by topoisomerase I. This leads to double strand DNA damage, which results in cell damage and cell death.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Topotecan (Hycamtin) patient drug information (Chemocare)[3]
- Topotecan (Hycamtin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 5/28/1996: Initial FDA approval